Physiomics PLC Contract award
May 14 2021 - 2:00AM
RNS Non-Regulatory
TIDMPYC
Physiomics PLC
14 May 2021
14 May 2021
Physiomics plc
("Physiomics") or ("the Company")
Contract award
Physiomics plc (AIM: PYC), the consultancy using mathematical
models to support the development of drug treatment regimens and
personalised medicine solutions, is pleased to announce that it has
been awarded a further contract by existing client Merck KGaA
("Merck") that it expects to be completed over the next two to
three months. This contract follows on from and is additional to
the initial tranche of projects with Merck announced on 17 December
2020, with a value of GBP270k, intended to be completed in the
first six to eight months of calendar year 2021. As has been its
practice since 2019, Merck has awarded contracts to Physiomics in
November or December to cover the first two to three quarters of
the following calendar year and then extended these or awarded new
contracts during the course of the year. The contract announced
today represents the first such extension and others will be
announced as and when they are agreed.
Enquiries:
Physiomics plc
Dr Jim Millen, CEO
+44 (0)1865 784 980
Hybridan LLP (broker)
Claire Louise Noyce
+44 (0) 203 764 2341
Strand Hanson Ltd (NOMAD)
James Dance & James Bellman
+44 (0)20 7409 3494
Notes to Editor
About Physiomics
Physiomics plc (AIM: PYC) is an oncology consultancy using
mathematical models to support the development of cancer treatment
regimens and personalised medicine solutions. The Company's Virtual
Tumour(TM) technology uses computer modelling to predict the
effects of cancer drugs and treatments to improve the success rate
of drug discovery and development projects while reducing time and
cost. The predictive capability of Physiomics' technologies have
been confirmed by over 80 projects, involving over 40 targets and
70 drugs, and has worked with clients such as Merck KGaA, Astellas,
Merck & Co and Bicycle Therapeutics.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAGPUQAAUPGGQW
(END) Dow Jones Newswires
May 14, 2021 02:00 ET (06:00 GMT)
Physiomics (LSE:PYC)
Historical Stock Chart
From Apr 2024 to May 2024
Physiomics (LSE:PYC)
Historical Stock Chart
From May 2023 to May 2024